Type 2 Diabetes (T2D) Clinical Trials

Find Type 2 Diabetes (T2D) Clinical Trials Near You

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Once-Weekly RO7795068 Administered to Participants With Obesity or Overweight Without Type 2 Diabetes

Status: Recruiting
Location: See all (22) locations...
Intervention Type: Combination product
Study Type: Interventional
Study Phase: Phase 3
SUMMARY

The purpose of this study is to assess the efficacy and safety of RO7795068, a dual glucagon like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (RA), at multiple doses compared with placebo for weight management in participants without Type 2 diabetes mellitus (T2DM) who have obesity or overweight with at least one weight-related comorbidity.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Participants must have at screening:

‣ Body mass index (BMI) greater than or equal to (≥)30.0 kg/m\^2; or

⁃ BMI ≥27.0 kg/m\^2 and \<30.0 kg/m\^2 with at least one weight-related comorbidity, such as prediabetes, hypertension, dyslipidemia, diagnosis of obstructive sleep apnea, or weight-related cardiovascular disease

• History of ≥1 self-reported unsuccessful diet/exercise effort to lose body weight

• Ability and willingness to self-administer the study drug (or receive an injection from a trained individual if visually impaired or with physical limitations)

Locations
United States
Alabama
Pinnacle Research Group
RECRUITING
Anniston
Arizona
Arizona Clinical Trials
RECRUITING
Tucson
California
Artemis Institute for Clinical Research, LLC
RECRUITING
San Diego
Illinois
Elevate Clinical Research
RECRUITING
Gurnee
Kentucky
Monroe Biomedical Research
RECRUITING
Louisville
Minnesota
International Diabetes Center At Park Nicollet
RECRUITING
Minneapolis
Missouri
Clinvest Research LLC
RECRUITING
Springfield
Oregon
Headlands Reseach- Summit
RECRUITING
Portland
South Carolina
Trial Management Associates
RECRUITING
Myrtle Beach
Tennessee
Clinical Research Associates
RECRUITING
Nashville
Texas
Elevate Clinical
RECRUITING
Houston
Elevate Clinical
RECRUITING
Mcallen
Other Locations
Australia
Paratus Clinical Western Sydney
RECRUITING
Blacktown
Canada
Wharton Medical Clinic
RECRUITING
Hamilton
Japan
Hasegawa Medicine Clinic
RECRUITING
Hokkaido
Higashijujo Sakai Diabetes Internal Medicine Clinic
RECRUITING
Tokyo
Taiwan
Changhua Christian Hospital
RECRUITING
Changhua
Chia-Yi Christian Hospital
RECRUITING
Chiayi City
China Medical University Hospital
RECRUITING
Taichung
Chung Shan Medical University Hospital
RECRUITING
Taichung
National Cheng Kung University Hospital
RECRUITING
Tainan
Taipei Veterans General Hospital
RECRUITING
Taipei
Contact Information
Primary
Reference Study ID Number: WC45725 https://forpatients.roche.com/
global-roche-genentech-trials@gene.com
888-662-6728 (U.S. Only)
Time Frame
Start Date: 2026-03-16
Estimated Completion Date: 2028-08-28
Participants
Target number of participants: 2000
Treatments
Placebo_comparator: Arm 1: Placebo
Experimental: Arm 2: RO7795068 Dosing Regimen 1
Experimental: Arm 3: RO7795068 Dosing Regimen 2
Experimental: Arm 4: RO7795068 Dosing Regimen 3
Related Therapeutic Areas
Sponsors
Leads: Hoffmann-La Roche

This content was sourced from clinicaltrials.gov